Delays in adopting new current procedural terminology codes cost one academic radiology practice hundreds of thousands of dollars in revenue, according to a new analysis.
Fear of COVID-19 and confusion over the capabilities of urgent care centers are still combining to lead some patients to make poor decisions over where they seek care, and just what level of care they really need. Evidence of this is clear in a report aired recently by KRGV television in the Rio Grande Valley region of Texas.
Radiology practices have a tremendous opportunity in 2021 to grow and invest in their businesses, and most importantly, to drive meaningful cost and quality improvement to the broader health care industry and to be a leader in providing value-based care.
When holding a time slot that could go to another paying customer, it’s common for service businesses to charge no-show or cancellation fees. With many urgent care centers moving to online registration and queuing systems, could this be a solution for maximizing throughput in urgent care as well?
Despite efforts to educate clinicians and increase payment revisions, little has changed in the amount spent on low-value healthcare for traditional fee-for-service Medicare patients.
Inaccurate or delayed diagnoses are the most common, most catastrophic and most costly of serious medical errors. The National Academy of Medicine believes “improving the diagnostic process is not only possible, but also represents a moral, professional and public health imperative.”
Advancements in artificial intelligence (AI) transform radiology with clinical decision support for imaging and increasing revenue through natural language understanding (NLU).
Published literature has shown the postponement and cancellation of elective procedures during the COVID-19 pandemic had a substantial financial impact on orthopedic practices and hospitals. In a study in International Orthopaedics, Matthew J. Best, MD, and colleagues estimated hospital losses of $10.9 to $11.9 billion in reimbursement and $2.6 to $3.5 billion in net income due to canceled elective musculoskeletal surgery during 8 weeks of the COVID-19 pandemic.
Follow-Up: Make the Case to Keep COVID-19 Testing in a Clinical Setting—for the Good of Patients and Your Practice
News that the Department of Defense and Department of Homeland Security were ready to plop down $230 million for at-home COVID-19 tests may have been great for the manufacturer, but it could have a deleterious effect on urgent care and other clinical settings that conduct testing—and on the patients the tests are designed to help, as well. The concern is that not all patients will be able to follow the instructions or be physically able to administer the test well enough to get reliable results.
Konica Minolta Healthcare Americas, Inc. announced an agreement with Medovate Ltd. to jointly promote Medovate’s SAFIRA™ regional anesthesia injection solution with Konica Minolta’s range of solutions for ultrasound-guided procedures in the USA. SAFIRA (Safer Injection for Regional Anesthesia) is a new medical device designed to limit injection pressure and automatically stop injection at high pressures, helping to reduce the risk of nerve injury and improving patient safety. This initiative is the latest addition to Konica Minolta’s UGPro® Solution, which brings together education, procedures and imaging equipment, such as the SONIMAGE® HS2 Compact Ultrasound System, to further expand the use of regional anesthesia and enhance patient safety.